Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam authorizes $1.0 billion buyback as Chief Commercialization Officer departs

Positive Impact 4 of 5 shareholder

Alnylam's board authorized a program to repurchase up to $1.0 billion of its common stock on November 2, 2026. The company also said Executive Vice President and Chief Commercialization Officer Tolga Tanguler will leave in December 2026, with a separation agreement still to be signed.

Key points

  • Board authorized a repurchase program of up to $1.0 billion of common stock on November 2, 2026.
  • The company anticipates repurchasing about $500 million by the end of 2026 and the balance during 2027.
  • The program has no expiration date and does not obligate the company to buy any particular amount; it may be modified, suspended or discontinued at any time.
  • Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, will depart in December 2026; the terms of his departure are yet to be set in a written agreement.

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:37 AM ET
Accession number0001178670-26-000080

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.